Lihteh Wu1,2, J Fernando Arevalo3, Mauricio Maia4, Maria H Berrocal5, Juan Sanchez3, Teodoro Evans6. 1. Instituto de Cirugia Ocular, San Jose, Costa Rica. LW65@CORNELL.EDU. 2. , Apdo 144-1225 Plaza Mayor, San Jose, Costa Rica, 1225. LW65@CORNELL.EDU. 3. Retina and Vitreous Service, Clinica Oftalmológica Centro Caracas, Caracas, Venezuela. 4. Departamento de Oftalmologia, Instituto da Visão, Universidade Federal de São Paulo, São Paulo, Brazil. 5. University of Puerto Rico, San Juan, Puerto Rico. 6. Instituto de Cirugia Ocular, San Jose, Costa Rica.
Abstract
PURPOSE: To compare the total number of injections and the anatomic and best-corrected visual acuity (VA) response after injecting 1.25 or 2.5 mg of bevacizumab as needed in patients with primary choroidal neovascularization secondary to age-related macular degeneration (AMD) at 12 months. METHODS: This was a retrospective, interventional, comparative multicenter study of 60 eyes treated with intravitreal bevacizumab (35 eyes, 1.25 mg; 25 eyes, 2.5 mg). RESULTS: The mean number of injections per eye was 3.8 in the 1.25-mg group and 3.2 in the 2.5-mg group (P = 0.2752). At 12 months, in the 1.25-mg group, 16 (46%) eyes gained > or =3 lines of Early Treatment Diabetic Retinopathy Study (ETDRS) VA and seven (20%) lost > or =3 lines of ETDRS VA. In the 2.5-mg group, 11 (44%) eyes improved by > or =3 lines, and four (16%) lost > or =3 lines (P = 1.000). At 12 months, in the 1.25-mg group, the mean central macular thickness decreased from 419 +/- 201 microm at baseline to 268 +/- 96 microm, compared with a decrease from 388 +/- 162 to 296 +/- 114 microm in the 2.5-mg group (P = 0.7896). CONCLUSION: There were no statistically significant differences between the two dose groups with regard to the number of injections, anatomic and VA outcomes.
PURPOSE: To compare the total number of injections and the anatomic and best-corrected visual acuity (VA) response after injecting 1.25 or 2.5 mg of bevacizumab as needed in patients with primary choroidal neovascularization secondary to age-related macular degeneration (AMD) at 12 months. METHODS: This was a retrospective, interventional, comparative multicenter study of 60 eyes treated with intravitreal bevacizumab (35 eyes, 1.25 mg; 25 eyes, 2.5 mg). RESULTS: The mean number of injections per eye was 3.8 in the 1.25-mg group and 3.2 in the 2.5-mg group (P = 0.2752). At 12 months, in the 1.25-mg group, 16 (46%) eyes gained > or =3 lines of Early Treatment Diabetic Retinopathy Study (ETDRS) VA and seven (20%) lost > or =3 lines of ETDRS VA. In the 2.5-mg group, 11 (44%) eyes improved by > or =3 lines, and four (16%) lost > or =3 lines (P = 1.000). At 12 months, in the 1.25-mg group, the mean central macular thickness decreased from 419 +/- 201 microm at baseline to 268 +/- 96 microm, compared with a decrease from 388 +/- 162 to 296 +/- 114 microm in the 2.5-mg group (P = 0.7896). CONCLUSION: There were no statistically significant differences between the two dose groups with regard to the number of injections, anatomic and VA outcomes.
Authors: F Giansanti; G Virgili; A Bini; E Rapizzi; G Giacomelli; M C Donati; T Verdina; U Menchini Journal: Eur J Ophthalmol Date: 2007 Mar-Apr Impact factor: 2.597
Authors: Ryan M Rich; Philip J Rosenfeld; Carmen A Puliafito; Sander R Dubovy; Janet L Davis; Harry W Flynn; Serafin Gonzalez; William J Feuer; Richard C Lin; Geeta A Lalwani; Jackie K Nguyen; Gaurav Kumar Journal: Retina Date: 2006 May-Jun Impact factor: 4.256
Authors: David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Stephan Michels; Philip J Rosenfeld; Carmen A Puliafito; Erin N Marcus; Anna S Venkatraman Journal: Ophthalmology Date: 2005-06 Impact factor: 12.079
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Iryna A Falkenstein; Lingyun Cheng; Victoria L Morrison; Igor Kozak; Ajay M Tammewar; William R Freeman Journal: Retina Date: 2007 Jul-Aug Impact factor: 4.256
Authors: Lihteh Wu; Arnaldo F Bordon; Martin Charles; Francisco J Rodríguez; JinKyung Lee; Tobias Machewitz; Margarete Mueller; Gabriela Del Carmen Gay; Jans Fromow-Guerra Journal: Int J Retina Vitreous Date: 2022-10-18